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Abstract
Introduction: Angiotensin II (AngII), a peptide that regulates the water-electrolytic balance and blood pressure, is also known to influence cell
proliferation. It can either induce cell growth, when binding to angiotensin type-I receptor, or trigger growth inhibition via angiotensin
type-II receptor. AngII stimulates proliferation of some normal and tumour cell lines, e.g. pituitary, adrenal glands and breast cancer.
Material and methods: The aim of this study was to evaluate possible AngII effect on the growth of two breast cancer cell lines —
hormone-dependent MCF-7 and hormone-independent MDA-MB-231. We measured tyrosine kinase activity as a potential proliferation
marker. We also estimated the influence of 17b-oestradiolon AngII-induced changes.
Results: In the MDA-MB-231 line, AngII radically slowed the activity of tyrosine kinases and 17b-oestradiol only at a concentration of 10–6 M,
while it  enhanced the effect of angiotensin II at a concentration of 10–9 M. In MCF-7, Ang II had a strong inhibitory effect in the presence
of oestradiol (10–6 M). Oestradiol alone decreased the activity of examined enzymes in both cell lines. AngII receptor type 1 was found in
both studied lines, but type 2 only in MDA-MB-231.
Conclusions: Our results show that AngII can modulate tyrosine kinase activity in breast tumour cell lines.
(Pol J Endocrinol 2011; 62 (2): 151–157)
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Streszczenie
Wstęp: Angiotensyna II (AngII), peptyd systemu renina-angiotensyna biorący udział w regulacji równowagi wodno-elektrolitowej oraz
ciśnienia krwi, jest także związkiem wpływającym na proliferację i wzrost komórek. Efekt działania tego peptydu uzależniony jest od
typu receptora. Angiotensyna II po związaniu z receptorem AT1 stymuluje proliferację i wzrost komórek natomiast poprzez aktywację
receptora AT2 — hamuje wzrost komórek oraz pobudza proces apoptozy. Proproliferacyjne działanie angiotensyny II zaobserwowano zarów-
no w komórkach tkanek zdrowych, jak i w komórkach nowotworowych między innymi komórkach przysadki i nadnerczy, ale także raka
piersi czy hiperplazji mięśni naczyń krwionośnych.
Materiał i metody: Celem pracy było zbadanie wpływu AngII na aktywność białkowych kinaz tyrozynowych dwóch linii nowotworo-
wych gruczołu piersiowego: hormono-zależnej linii MCF-7 i hormono-niezależnej MDA-MB-231. Aktywność kinaz tyrozynowych jest
przyjętym markerem proliferacji. Oszacowano także wpływ 17b-estradiolu na zmiany w aktywności kinaz tyrozynowych wywołane
angiotensyną II.
Wyniki: AngII radykalnie hamowała aktywności kinaz tyrozynowych w linii MDA-MB-231, natomiast 17b-estradiol tylko w stężeniu 10–6 M
pogłębiał efekt działania angiotensyny II w stężeniu 10–9 M. W linii hormono-zależnej MCF-7 Ang II miała silny hamujący wpływ na
aktywność badanych enzymów w obecności estradiolu 10–6 M. Sam estradiol obniżał aktywność badanych enzymów w obu liniach ko-
mórkowych. Obecność receptora angiotensynowego typu 1 została potwierdzona w obydwu badanych liniach raka piersi, natomiast
ekspresję receptora typu 2 odnotowano jedynie w komórkach MDA-MB-231.
Wnioski: Otrzymane wyniki wskazują, że AngII może modulować aktywność kinaz tyrozynowych w badanych komórkach raka gruczo-
łu sutkowego. (Endokrynol Pol 2011; 62 (2): 151–157)
Słowa kluczowe: angiotensyna, rak piersi, MDA-MB-231, MCF-7, 17b-estradiol, PTKs
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Introduction
In classical terms, the central renin-angiotensin system
(RAS) works as a co-ordinated cascade, which mainly
controls the cardiovascular, renal and adrenal functions.
Angiotensin II (AngII) is its principal effector hormone.
AngII can either induce cell growth and proliferation
by binding to the angiotensin type-1 receptor (AT1R),
or can cause an opposite effect: growth inhibition and
stimulation of apoptosis via the angiotensin type-2 re-
ceptor (AT2R) [1].
It has recently been shown that many structures
have local renin-angiotensin systems. All components
of RAS, including angiotensinogen, prorenin, ACE and
two main angiotensin receptors (AT1R and AT2R) have
been found both in normal cells and in different types
of tumour cells, including breast tumour cells [2]. These
local systems could be involved in the pathogenesis of
cancer and might play an important role in controlling
cell growth [2, 3]. The proliferogenic action of AngII is
not limited to the circulatory system: various studies
have demonstrated this peptide can modulate prolifer-
ation of adrenocortical, endometrial and anterior pitu-
itary cells as well [4–6]. AngII also appears to be a po-
tentially important growth promoter, since in a variety
of cell types it activates phosphatidylinositol turnover,
causing a rise in cytosolic Ca2+, a process linked to mi-
togenesis [7]. In the oestrogen-dependent breast can-
cer cell line MCF-7, AngII is responsible for induction
of cell growth, probably via AT1R receptors. It is pre-
sumed that the two main second messengers for AT1R
are triphosphoinositol (IP3) and diacylglycerol, both of
which activate protein kinase C (PKC) [1]. The propro-
liferative effects of AngII, after binding to AT1R, could
be connected to activation of PKC. Another intracellu-
lar mechanism by which angiotensin peptides can con-
trol cell growth is modulation of protein tyrosine kinas-
es (PTKs). Tyrosine kinases are coupled to the receptors
of several growth factors and are involved in the trans-
duction of growth inducing signals. AngII, acting via
classical AT1R receptors, may modulate cell growth [8,
9] and tyrosine kinase activity [10–12] in various nor-
mal and cancer tissues, such as vascular muscle cells,
a normal and tumoral pituitary gland and a hormone–
–independent prostate cancer. There is also evidence
that AngII-induced biological effects may depend on
the concentration and presence of gonadal steroids [13].
The aim of this study was to examine the effect of
AngII on tyrosine kinase activity in oestrogen-depen-
dent and oestrogen-independent breast cancer cells and
the influence of 17b-oestradiol on AngII-induced chang-
es. Additionally, we checked if classical AngII receptors
are present in these cell lines. The modulatory effect of
AngII on PTKs activity in two cell lines of breast tumours,
hormone-independent MDA-MB-231 and hormone-
dependent MCF-7, is reported for the first time in the
present study.
Material and methods
The radioactive g-32P — ATP was purchased from Iso-
topes Center (Hungary).
Cell culture
Breast cancer-derived cell lines, purchased from the
American Type Culture Collection (ATCC), were kind-
ly donated by Prof. Andrzej Bednarek from the Depart-
ment of Molecular Carcinogenesis, Medical University
of Lodz, Poland. MCF-7 cells were cultured in DMEM
supplemented with 10% foetal bovine serum; MDA-
-MB-231 cells were maintained in McCoy’s medium. The
cell lines were cultured under standard conditions (5%
CO2 at 37°C). The media and other cell culture reagents
were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Phosphorylation assay
300,000 cells per sample were sonicated in medium con-
taining 0.32 M sacharose, 0.05 mM EDTA, 10 mM TRIS/
/HCl pH 7.4, 0.05 mM PMSF and aprotinin 25 KIU/ml at
4°C. The samples were preincubated for 15 min at 37°C
with angiotensin II alone at several concentrations
(10–11 M–10–9 M), and with 17b-oestradiol at concentrations
of 10–5 M and 10–6 M, added to the mixture separately or
together with AngII. Then 0.1% TRITON-X –100 was
added to all samples for 15 min (0°C). The reaction me-
dium contained: 20 mM TRIS/HCl pH 7.4; 20 mM
MgCl2; 1 mM MnCl2; 1 mM EGTA; 0.5 mM EDTA;
0.1 M DDT, 1 mM ouabain and 1 mM sodium ortho-
vanadate [14]. The phosphorylation was initiated by
adding g-[32P] – ATP (200 mM) to the mixture contain-
ing the preincubated cells and an artificial specific sub-
strate for tyrosine kinases — polyGlu,Tyr in a ratio of
4:1. The control group did not contain the substrate.
Incubation was carried out for 7 min at 30°C and then it
was stopped by adding a dissociation buffer with 5 mM
ATP and 0.25 mM EDTA. The reaction mixture was
spotted onto Whatman 3MM paper and washed three
times with cold 10% TCA with 5% sodium pyrophos-
phate. The radioactivity of 32P incorporated into the
substrate was counted as Cerenkov radiation in liq-
uid scintillation analyser. The activity of protein ty-
rosine kinase was defined as the amount of pmoles of
32P incorporated into polyGlu,Tyr per mg of protein
during 1 min. The results were compared to the basal
activity of protein tyrosine kinase obtained from sam-
ples which did not contain any of the studied com-
pounds. The degree of 32P incorporation by PTKs into
the specific substrate in the control group (basal activi-
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ty) was assumed to be 100% and averaged to approx-
imately 300 pmoles/mg/min.
Source of RNA
The research was carried out on two human breast can-
cer cell lines: MCF-7 and MDA-MB-231 (2 × 106 cells
per RNA isolation). RNA was extracted using Trizol®
reagent (InvitrogenTM, Carlsbad, CA, USA) according to
the manufacturer’s guidelines. Two independent extrac-
tions from each type of cell were performed in this
study. The concentrations of the resulting RNA sam-
ples were determined by spectrophotometric measure-
ments (Beckman DU-650).
cDNA synthesis
Synthesis of cDNA was performed from 10 µg of total
RNA in a total volume of 70 µl using ImProm-IITM re-
verse transcriptase (Promega, Madison, WI, USA). Next,
cDNA samples were diluted with sterile deionised wa-
ter to a total volume of 140 µl. Volumes of 2.5 µl (corre-
sponding to 0.18 µg of total RNA) were used for PCR.
PCR technique
Reactions were performed according to the manufac-
turer’s instructions. The 25 ml volume of reaction mix-
ture contained 2.5 ml of cDNA (non-diluted or 10-fold
diluted for AT1R-specific, AT2R-specific and b actin-
specific PCR, respectively), primers (0.5 mM each), and
2 mM MgCl2. A typical protocol included 3 min of ini-
tial denaturation followed by 45 cycles of 94°C dena-
turation for 40 min, annealing at 55/60/65°C (depend-
ing on the PCR product) for 40 min and extension at
72° for 40 min. The sequences of primers and annealing
temperatures are presented in Table I. The sequences
of primers and the length of PCR product for AT1R and
AT2R were designed using AMPLIFY 3.1.4 For MacOS
X program. The primers for b-actin were as described
by Robert et al. [15]. All reactions were performed in
duplicate. The PCR products were confirmed by mo-
lecular weight determination under UV light after elec-
trophoresis in 10% polyacrylamide gel. As a first step,
all cDNA preparations were used as templates for PCR
with b-actin-specific primers to evaluate whether the
constitutively expressed gene could be amplified from
the preparations. AT1R-specific RT-PCR experiment
was accompanied by an identical reaction prepared with
total RNA isolated from DU-145, a hormone-indepen-
dent prostate cancer cell line, where the presence of
AT1R expression has previously been documented [16].
Statistical evaluation
All data is expressed as means ± SD. Statistical signifi-
cance was assessed by analysis of variance (One-Way
ANOVA) for repeated measurements followed by the
LSD (Least Significant Difference) post-hoc test to de-
termine the extent of the differences with the use of the
StatGraphics Plus 6.0. A significance level of 5% was
chosen (p < 0.05).
Results
The basic activities of PTKs did not differ between the
studied cell lines. The concentration-dependent effects
of AngII on tyrosine kinase activity in MCF-7 and MDA-
-MB-231 are presented in Figure 1. As can be seen, the
Table I. Oligonucleotides used for PCR
Tabela 1. Sekwencje starterowe zastosowane w łańcuchowej
reakcji polimerazy
Gene primers (5’> 3’) Annealing PCR product
temperature (°C)  size (bp)
Angiotensin II receptor
type 1 (AT1R)
AGC CGG CCC TCG GCG 65 126/235
GGA CGTG TCA TTT TGA
TCA CCT GGG TCG AAT
TTG TTG C
Angiotensin II receptor
type 2 (AT2R)
TTC TGC AGC CTG AAT 60 147
TTT GAA GGA GTG TG
AGT AGT GGC AAG GGT
GGA GTT GCC CTT C
b-actin
CGTGACATTAAGGAGA 55 374
AGCTGTGC
CTCAGGAGGAGCAATG
ATCTTGAT
Figure 1. The effect of angiotensin II on protein tyrosine kinase
activity in MDA-MB-231 and MCF-7 cell lines. X ± SD; *p < 0.05
**p < 0.01, ***p < 0.001 vs. C
Rycina 1. Wpływ angiotensyny II na aktywność białkowych kinaz
tyrozynowych w komórkach linii MDA-MB-231 i MCF-7. X ± SD;
*p < 0,05, **p < 0,01, ***p < 0,001 v. C
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activity of the studied enzymes in the oestrogen-inde-
pendent cell line MDA-MB-231 was strongly reduced
by the peptide.
In MDA-MB-231, the presence of 17-ßoestradiol (E2)
only at a concentration of 10-6 M changed significantly the
AngII (10–9 M)-induced effect on PTKs activity (Fig. 2).
Figure 2. The effect of angiotensin II on protein tyrosine kinase activity in the hormone-independent cell line MDA-MB-231 in the
presence of 17b-oestradiol. X ± SD; *p < 0.05, **p < 0.01, ***p < 0.001
Rycina 2. Wpływ angiotensyny II na aktywność białkowych kinaz tyrozynowych w hormono-niezależnej linii komórkowej MDA-MB-
231 w obecności 17ß-estradiolu. X ± SD; *p < 0,05, **p < 0,01, ***p < 0,001
Figure 3. The effect of angiotensin II on protein tyrosine kinase activity in the hormone-dependent cell line MCF-7 in the presence of
17b-oestradiol. X ± SD; *p < 0.05, **p < 0.01, ***p < 0.001
Rycina 3. Wpływ angiotensyny II na aktywność białkowych kinaz tyrozynowych w hormono-zależnej linii komórkowej MCF-7
w obecności 17b-estradiolu. X ± SD; *p < 0,05, **p < 0,01, ***p < 0,001
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In MCF-7, the oestrogen-dependent cancer cell line,
E2 at the concentration of 10
–5 M reversed the effect of
AngII (10–9 M and 10–10 M) (Fig. 3). However, preincu-
bation with E2 at the concentration of 10
-6 M enhanced
AngII-induced changes in PTKs activity (AngII 10–9,
10–10 M) (Fig. 3). Preincubation with 17-boestradiol alone
lowered PTKs activity in both studied cell lines and the
inhibition was much stronger at the concentration of
10–5 M than at 10–6 M (Figs. 2 and 3).
Figure 4 illustrates the presence of mRNA for clas-
sical AngII receptors, AT1R and AT2R, in both stud-
ied cell lines. In order to examine both cell lines for
the expression of the type 1 and 2 angiotensin II recep-
tors, we performed receptor-specific RT-PCR using
total RNA isolated from MCF-7 and MDA-MB-231
cells obtained from b-actin-specific PCR product of
374 bp as shown in Fig. 4A. AT1R-specific PCR ga-ve
positive results for MCF-7-, MDA-MB-231- and
DU145-derived cDNA. As shown in Fig. 4B, AT1R-
-specific PCR products of 126 bp were observed in
both types of cDNA preparations, and an additional
product of 235 bp was detected only in MCF-7-de-
rived cDNA.
AT2R-specific primers were applied in the search for
the expression of angiotensin II receptor type 2 in both
cell lines. Independently of applied PCR conditions,
AT2R-specific PCR product of the expected length of
147 bp was observed only for MDA-MB-231 cDNA,
whereas MCF-7-derived cDNA did not exhibit AT2R ex-
pression at a level sufficient for PCR detection (Fig. 4C).
Discussion
Breast cancer is the most commonly diagnosed cancer
among women in Western countries. The renin-angio-
tensin system plays an important role in water and elec-
trolyte homeostasis and its main effector (AngII) has been
recently attributed with angiogenic and growth factor
actions in a breast tissue. AngII originated from its pre-
cursor by angiotensin I-converting enzyme (ACE) has
been recently shown to mediate growth of breast cancer
cell lines via ligand-induced activation of the angiotensin
II Type I receptor [17]. Another effect of AngII in breast
cancer is the reduction of apoptosis. In the MCF-7 cell
line, AngII suppressed adriamycin-induced apoptosis via
AT1 receptor and protein kinase cascade [18]. Activation
of tyrosine kinases (PTKs) and phospholipase C (PKC) is
a part of the second messenger dependent response af-
ter AngII has been bound to AT1 receptor.
Our data shows for the first time that AngII inhibits
PTKs activity in breast cancer cell lines. It is worth un-
derlining that such an effect was clearly evident in the
oestrogen-independent cell line MDA-MB-231 (all re-
sults were highly significant: p < 0.001). On the other
hand, in the MCF-7 cell line, AngII alone did not change
significantly the basal PTKs activity (AngII at concen-
trations of 10–11M) or had a weak inhibitory effect (AngII
at concentrations of 10–9 and10–10M). Generally, the re-
sults were surprising, because AngII is known to stim-
ulate cell proliferation (including breast cancer cells),
thus we in fact expected an increase in PTKs activity.
Figure 4. Electrophoregram of PCR products of angiotensin II receptors, AT1R and AT2R, in both studied cell lines (MDA-MB-231
and MCF-7). A. b-actin-specific PCR products: lane 1, HL60 (positive control; PCR product — 374 bp); lane 2, DNA size markers; lane
3, MDA-MB-231 (PCR product — 374 bp); lane 4, MCF-7 (PCR product — 374 bp); lane 5, H2O (negative control). B. AT1R-specific
PCR products: lane 1, DU145 (positive control; PCR product — 126 bp); lane 2, MCF-7 (PCR products — 126 bp and 235 bp); lane 3,
MDA-MB-231 (PCR product — 126 bp); lane 4, DNA size markers; lane 5, H2O (negative control). C. AT2R-specific PCR products:
lane 1, H2O (negative control); lane 2, MDA-MB-231 (PCR product — 147 bp); lane 3, MCF-7 (lack of PCR product — 147 bp); lane 4,
DNA size markers
Rycina 4. Elektroforegram przedstawiający produkty PCR dla receptorów angiotensyny II (AT1R i AT2R) w obydwu badanych liniach
(MDA-MB-231 i MCF-7). A. Produkty PCR dla b-aktyny: kanał 1, HL60 (kontrola pozytywna; produkt PCR — 374 pz); kanał 2:
wzorce; kanał 3: MDA-MB-231 (produkt PCR — 374 pz); kanał 4: MCF-7 (produkt PCR — 374 pz), kanał 5: H2O (kontrola negatywna).
B. Produkty PCR dla AT1R: kanał 1, DU145 (kontrola pozytywna; produkt PCR — 126 pz); kanał 2: MCF-7 (produkt PCR — 126 pz
i 235 pz), kanał 3: MDA-MB-231 (produkt PCR — 126 pz); kanał 4: wzorce; kanał 5: H2O (kontrola negatywna). C. Produkty PCR dla
AT2R: kanał 1: H2O (kontrola negatywna), kanał 2: MDA-MB-231 (produkt PCR — 147 pz), kanał 3: MCF-7 (brak produktu PCR —
147 pz ), kanał 5: wzorce
A B C
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The technique used provides global information on
the level of activation of a large pool of non-receptor
tyrosine kinases, e.g. Src, Jak, Fak, Pyk2, and Abl. All of
them are involved in such processes in cells as: prolifer-
ation, growth, differentiation, and apoptosis. It is pos-
sible that some of these kinases can be inhibited by AngII
but another can be activated. In most cases, PTKs activ-
ity may represent a potentially useful proliferation
marker. Our earlier study showed that phosphoryla-
tion assay can give results analogous to those derived
from MTT assay. In both methods, we observed similar
effects of angiotensin on a hormone-dependent pros-
tate cancer cell line (LNCaP) [12].
It is worth noting that the proproliferative action of
peptides from the family of angiotensins is a result of
the activation exclusively of the receptor AT1R. The ac-
tivation of the receptor AT2R leads rather to the stimu-
lation of apoptosis. Additionally, AT1R and AT2R are
capable of forming heterodimers, where through AT2R
abolishes functions of the receptor AT1R and is consid-
ered to be a his antagonist [19].
This could be the reason why in the cellular line
MDA-MB-231, in which we detected expressions of both
types of receptor, the activity of tyrosine kinases was
significantly decreased. In the line MCF-7, in which we
did not observe the expression of the receptor AT2A,
the effect of AngII was significantly weaker but so also
was the inhibition of the activity of examined enzymes.
Moreover, we detected two AT1R-specific PCR prod-
ucts in MCF-7. This suggests that the expression of two
AT1R-specific mRNA variants might be a characteristic
feature of that cell line and the additional variant could
be responsible for this inhibitory effect of AngII. It might
be connected to the invasiveness of the cancer. In ad-
vanced breast cancer cells, where regulatory pathways
initiated by AngII are not needed, expression of AT1R
on the cell membrane disappears. However De Paepe
et al. suggested that specific overexpression of AT1R
receptor on the cell membrane can occur in cells of hy-
perplastic lesions with and without atypia [20].
The most active oestrogen, 17b-oestradiol, is in-
volved in tumour cell proliferation and breast cancer
development. It has been reported that enzymes which
synthesise oestradiol by both aromatase and sulfatase
pathways, (especially 17b-hydroxysteroid dehydrogena-
ses) are very important in the development of breast can-
cer, including MCF-7 and MDA-MB-231 cell lines [21].
The effect of oestradiol on tyrosine kinase activity
in the presence of AngII has not been studied. Never-
theless, it has been reported that this steroid hormone
can affect the activities of other physiological com-
pounds involved in breast cancer growth. For exam-
ple, it has been found that 17b-oestradiol can modify
the expression of adiponectin receptor and adiponec-
tin action on cell growth in MCF-7 and MDA-MB-231
cells [22]. Moreover, oestradiol can modulate the bio-
logical properties of local RAS, too. For example, Pawl-
ikowski et al. demonstrated significant differences be-
tween the AngII effects on the adrenocortical cell pro-
liferation in ovariectomised and intact rats [23]. Previ-
ous publications also indicated that sensitivity of tissues
to angiotensins is modulated by the steroid hormone
[13, 24].
In both studied cell lines, E2 alone strongly reduced
PTKs activity. The term — ‘oestrogen-dependent line’
usually means that cells show the expression of the clas-
sical receptor for the hormone and effects are the result
of the genomic way of oestrogen action. But in hor-
mone-sensitive cells, receptors for steroid hormones are
present not only in the nucleus or cytosol but also in
the cell membrane. Steroid hormone action using mem-
brane receptors is a fast way of signal transmission and
is called non-genomic [25]. Oestradiol may bind not only
to its own specific membrane receptor, but also to vari-
ous G-protein-coupled receptors similar to AT1R and
AT2R [26]. For instance, in oestrogen-receptor negative
breast cancer cells, oestradiol can modify cell functions
via AT1R [27].
We can assume that the oestrogen-induced effects
on PTKs activity observed by us were in fact non-ge-
nomic rather than genomic, bearing in mind the short
time (15 min) of incubation with oestradiol and the fact
that steroid can modify AngII — receptor interaction.
In our work preincubation of hormone-independent
MDA-MB-231 cell line with oestradiol (10–6 M) in fact
did not change the inhibitory effect of AngII on PTKs
activity (AngII at concentrations of 10–10 and10–11M) and
slightly enhanced the inhibitory effect only of AngII at
a concentration of 10–9 M.
Although E2 alone (at a concentration of 10
–5 M)
strongly reduced PTKs activity in hormone-dependent
MCF-7 cell line, such high concentration of steroid re-
versed the inhibitory effect of AngII. A ten times lower
concentration of E2 in the presence of AngII decreased
PTKs activity much more strongly than AngII alone. The
simplest explanation for this discrepancy is that the
observed effects probably depend on the type of AngII
receptors present in the studied cancer cell lines.
In MCF-7, we detected two AT1R-specific PCR prod-
ucts, but none corresponding to AT2R. Specific AT1R
and AT2R products were detected in MDA-MB-231. The
absence of AT2R might be responsible for the slight in-
hibitory effect of AngII alone in MCF-7 cells. In MDA-
-MB-231cell line, in which we detected AT2R, binding
of AngII to that receptor may result in a decrease in PTKs
activity and may inhibit proliferation.
On the other hand, the mechanism of inhibition of
PTKs activity by AngII may be more complicated. The
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RAS system, including the density of AngII receptors,
is sex-hormone sensitive. Thus, we cannot exclude the
influence of steroid hormones or steroid hormone re-
ceptors on AngII action in the cells. Our earlier study
revealed that AngII decreased in PTKs activity in the
hormone-independent prostate cancer cell line DU-145
(similarly to the effect reported for MDA-MB-231 in the
present work), although we did not detect the presence
of AT2R in DU-145 [16]. In a hormone-dependent pros-
tate cancer line (LNCaP) AngII did not change PTKs
activity, similar to AngII action in MCF-7 [12].
We cannot also exclude the possibility of downreg-
ulation of AT1R mRNA expression in hormone-depen-
dent cell lines, but additional studies are needed to in-
vestigate the influence of steroid hormones on the ex-
pression of AT1 and AT2 receptor in hormone-depen-
dent and hormone-independent cell lines.
It is known that long exposure to oestrogens down-
regulates AT1R receptor expression [28] and that oestra-
diol influences ACE1, ACE2, AT1R and AT2R in kid-
neys, lungs and hearts and that this effect is tissue-de-
pendent [29, 30]. The upregulation of specific AT1R and
AT2R expression might well be an important step in
the pathogenesis of hyperplasia and breast cancer. The
drugs used in the treatment of hypertension (such as
AngII receptor blockers and inhibitors of enzymes in-
volved in angiotensin metabolism) can reduce tumour
size but they are not sufficiently effective. New and
more effective compounds are still needed which could
be used in breast tumour therapy and act via RAS. One
of them could be a shorter fragment of anti-AT1R anti-
body [31].
Conclusions
The enzymes involved in intracellular signalling asso-
ciated with angiotensin receptor activation, including
tyrosine kinases, could be the next target for anti-can-
cer drugs.
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